Literature DB >> 9508193

Prospective investigation of positron emission tomography in lung nodules.

V J Lowe1, J W Fletcher, L Gobar, M Lawson, P Kirchner, P Valk, J Karis, K Hubner, D Delbeke, E V Heiberg, E F Patz, R E Coleman.   

Abstract

PURPOSE: Solitary pulmonary nodules (SPNs) are commonly identified by chest radiographs and computed tomography (CT). Biopsies are often performed to evaluate the nodules further. An accurate, noninvasive diagnostic test could avoid the morbidity and costs of invasive tissue sampling. We evaluated the ability of fluorine-18 deoxyglucose positron emission tomography (FDG-PET) to discriminate between benign and malignant pulmonary nodules in a prospective, multicenter trial.
METHODS: Eighty-nine patients who had newly identified indeterminate SPNs on chest radiographs and CT were evaluated with FDG-PET. PET data were analyzed semiquantitatively by calculating standardized uptake values (SUVs) as an index of FDG accumulation and also by a visual scoring method. PET results were compared with pathology results.
RESULTS: Sixty SPNs were malignant and 29 were benign. Using SUV data, PET had an overall sensitivity and specificity for detection of malignant nodules of 92% and 90%. Visual analysis provided a slightly higher, but not statistically significant, sensitivity of 98% and lower specificity of 69%. For SPNs < or = 1.5 cm (34 of 89), the sensitivity and specificity of SUV and visual analysis were 80% and 95% and 100% and 74%, respectively.
CONCLUSION: FDG-PET can accurately characterize indeterminate SPNs. PET imaging provides a noninvasive method to evaluate indeterminate SPNs, which can reduce the need for invasive tissue biopsy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508193     DOI: 10.1200/JCO.1998.16.3.1075

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  77 in total

1.  Is quantitation necessary for oncological PET studies? For.

Authors:  R Edward Coleman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2001-11-14       Impact factor: 9.236

2.  Is quantitation necessary for oncological PET studies? Against.

Authors:  Michael M Graham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01       Impact factor: 9.236

Review 3.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

Review 4.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

5.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 6.  Management of an incidentally discovered pulmonary nodule.

Authors:  Catherine Beigelman-Aubry; Catherine Hill; Philippe A Grenier
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

7.  A hybrid algorithm for PET/CT image merger in hybrid scanners.

Authors:  John A Kennedy; Ora Israel; Alex Frenkel; Rachel Bar-Shalom; Haim Azhari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

Review 8.  The pulmonary nodule: clinical and radiological characteristics affecting a diagnosis of malignancy.

Authors:  L Cardinale; F Ardissone; S Novello; M Busso; F Solitro; M Longo; D Sardo; M Giors; C Fava
Journal:  Radiol Med       Date:  2009-05-29       Impact factor: 3.469

9.  Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.

Authors:  M G Caprio; A Cangiano; M Imbriaco; F Soscia; G Di Martino; A Farina; G Avitabile; L Pace; P Forestieri; M Salvatore
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

Review 10.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.